<p>Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study</p>

Abstract

These authors contributed equally to this workBackground: The aim of this study was to evaluate the efficacy and safety of trastuzumab, combined with the FLOT regimen, in the perioperative treatment of resectable HER-2-positive advanced gastric cancer. Methods: Overall, 45 patients were divided into two groups; 29 patients in the experimental group were treated with trastuzumab combined with FLOT and 16 patients in the control group were treated with FLOT alone. The primary endpoint was objective response rate (ORR), and the secondary endpoints were disease control rate (DCR), tumor regression grade (TRG), surgical margin, side effects, and overall survival. Results: In the experimental and control groups, ORR was 72.4% and 43.8% (p=0.226), DCR was 89.7% and 87.5%, R0 resection rate was 96.5% and 93.7%, total/subtotal tumor regression grade was 17.2% and 6.3%, partial tumor regression grade was 27.6% and 18.7% (p=0.468), and 2-year survival rate was 78.1% and 73.9% (p=0.932), respectively. The common side effects were agranulocytosis and vomiting. There was no significant difference between the two groups. Conclusion: Trastuzumab combined with FLOT has a good curative effect and safety profile in the perioperative treatment of patients with resectable HER-2-positive advanced gastric cancer. In addition, trastuzumab + FLOT had the same result as FLOT alone, as there was no significant benefit with the addition of T in the group studied.

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing

“…The 2-year OS rates were 78.1% and 73.9%, respectively (p = 0.932). Although the study did not reach statistical significance in primary and ancillary endpoints, the addition of trastuzumab provided a numerically high tumor response rate and a promising pathological regression compared to the control group: the tumor regression rate to grade Ia/Ib was obtained in 44.8% of patients [27].…”

A case report on the long-term survival of a patient with HER2-positive metastatic gastric adenocarcinoma and a short review of the current literature

“…This regimen can be considered as first-line therapy for patients with an excellent performance status. Furthermore, there were several trials to evaluate the role of HER2-targeted therapies in a first-line resectable setting of gastroesophageal adenocarcinoma; however, so far there have been no practice-changing results [2,3].…”